Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02057133
Title A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company

Her2-receptor negative breast cancer

Her2-receptor positive breast cancer


Abemaciclib + Loperamide + Pertuzumab + Trastuzumab

Abemaciclib + Fulvestrant + LY3023414

Abemaciclib + Letrozole

Abemaciclib + Exemestane


Abemaciclib + Everolimus + Exemestane

Abemaciclib + Anastrozole

Abemaciclib + Tamoxifen

Abemaciclib + Trastuzumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.